Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review
Combining two targeted therapies works in aggressive leukemia cases previously resistant to single agents, suggesting a new treatment path.
This case report describes two patients with Richter's syndrome treated with BTK inhibitor and bispecific antibody combination, an emerging approach for this aggressive CLL transformation. A mini review of available evidence accompanies the cases.
What the study was
- Study design
- Case report + mini review
- Population
- Richter's syndrome patients
- Sample size
- 2
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cureus
Why it surfaced
Case series capped at 4 per rubric. Richter's syndrome is high unmet need but n=2 severely limits evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.